Vir Biotechnology, GSK Terminate Collaboration on Flu
By Denny Jacob
Vir Biotechnology and GSK terminated their collaboration regarding the flu.
The clinical-stage immunology company and GSK collaborated to research, develop and commercialize Vir's monoclonal antibodies for the prevention, treatment or prophylaxis of the influenza virus under an agreement established in May 2021.
Vir said the change reflects that it retains sole rights to continue advancing its investigational therapies for influenza independently or with other partners. The company added that it's actively pursuing external partnership opportunities for its next-generation influenza A and B antibodies and antibody drug conjugates.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 22, 2024 16:57 ET (21:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now